Andy Hsieh

Q: What is the average return of Andy Hsieh's calls?

Their stock ratings have generated an average return of 18.06747223062093.

William Blair | Healthcare

Andy Hsieh is an analyst from William Blair specializing in the Healthcare sector. They are beginning to establish their track record, with 3 stock ratings so far. Their current stats show a success rate of 0.00% and an average return of 18.07%.

Andy Hsieh has only issued 3 ratings so far. While the sample size is small, their early calls show a success rate of 0.00% and an average return of 18.07%. Investors may find their initial activity in the Healthcare sector worth watching as they build a track record.

#21790

Out of 4771

Total Ratings

Success Rate

+18.07%

Average Return

Recent Ratings Analysis

AARD

Buy

Dec 12, 2025

Target

—

Current

$5.01

Performance

-65.28%

Andy Hsieh rated AARD as Outperform on Dec 12, 2025, setting a price target of null. The stock has underperformed, dropping 65.28% despite the bullish target of null.

TERN

Buy

Nov 03, 2025

Target

—

Current

$52.95

Performance

277.41%

On Nov 03, 2025, TERN was given a Outperform rating by Andy Hsieh, with a target price of null. The stock rallied 277.41% after the rating, narrowing the gap to the target of null and validating the bullish stance.

ELEV

Hold

Jun 09, 2025

Target

—

Current

$0.36

Performance

-5.02%

ELEV received a Market Perform rating from Andy Hsieh on Jun 09, 2025, aiming for null. The Hold stance proved prudent, with the market softening by 5.02%.

ALT

Hold

Feb 28, 2025

Target

—

Current

$3.29

Performance

-50.53%

On Feb 28, 2025, Andy Hsieh published a Market Perform outlook on ALT, with a target of null. Weakness in the stock, now at 3.29, supported the conservative rating.

BIOA

Hold

Feb 28, 2025

Target

—

Current

$8.65

Performance

86.83%

Andy Hsieh on Feb 28, 2025 assigned BIOA a Market Perform rating, with a price target of null. Shares outperformed expectations, climbing 86.83% despite the neutral view.

GPCR

Buy

Feb 28, 2025

Target

—

Current

$39.55

Performance

66.53%

On Feb 28, 2025, Andy Hsieh reaffirmed GPCR with a Outperform rating, targeting null. The recommendation was supported by strong follow-through as the stock rose from 39.55 to 39.55.

CRBP

Buy

Feb 28, 2025

Target

—

Current

$8.24

Performance

9.14%

CRBP was rated Outperform by Andy Hsieh on Feb 28, 2025, with a price objective of null. A bullish response from the market helped close the gap of -8.24 to the target.

SKYE

Buy

Feb 28, 2025

Target

—

Current

$2.08

Performance

-90.88%

On Feb 28, 2025, Andy Hsieh initiated coverage on SKYE with a Outperform rating and target of null. The Buy call has yet to be validated as shares remain -2.08 away from the target.

MRSN

Buy

Feb 06, 2025

Target

—

Current

$29.08

Performance

4152.71%

Andy Hsieh issued a Outperform recommendation for MRSN on Feb 06, 2025, price target set at null. Investors following the Buy call captured upside momentum, with shares now at 29.08.

PYXS

Hold

Nov 21, 2024

Target

—

Current

$3.27

Performance

55.71%

On Nov 21, 2024, PYXS was evaluated by Andy Hsieh, who gave a Market Perform rating and target of null. Investors who stayed in despite the Hold saw upside of 55.71%.

Frequency Asked Questions

Who is Andy Hsieh?

Andy Hsieh is an analyst from William Blair specializing in the Healthcare sector.

What is Andy Hsieh's success rate?

Andy Hsieh currently has a success rate of 0.

How many ratings has Andy Hsieh issued?

Andy Hsieh has issued 3 stock ratings so far.

What is the average return of Andy Hsieh's calls?

Their stock ratings have generated an average return of +18.07%.

What is Andy Hsieh's ranking?

Andy Hsieh is ranked #21790 out of 4771 analysts.

What types of ratings does Andy Hsieh give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Andy Hsieh?

You can follow Andy Hsieh by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Andy Hsieh?

Their latest rating was a Buy on AARD issued on 2025-12-12.